Anthera Pharmaceuticals, Inc. (ANTH) added to 6 new portfolios

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) produced a 58.33% rally since recording the worst price of $1.2. Thanks to the latest 32.87% increase, it now trades at $1.9. Throughout the trading on Oct. 3, 2017, the share price floated between $1.43 and $1.94. This company shares are 255.26% off its target price of $6.75 and the current market capitalization stands at $20.58M. The recent change has given its price a 37.79% lead over SMA 50 and -93.06% deficit over its 52-week high. The stock witnessed 26.67% gains, 18.75% gains and -43.44% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANTH’s volatility during a week at 11.43% and during a month it has been found around 7.97%.

Anthera Pharmaceuticals, Inc. (ANTH) Top Holders

Institutional investors currently hold around $4 million or 29.2% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $1.44 million in Anthera Pharmaceuticals, Inc., which represents roughly 6.99% of the company’s market cap and approximately 35.98% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 592,672 shares of the stock are valued at $848 thousand. The third largest holder is Vanguard Group Inc, which currently holds $488 thousand worth of this stock and that ownership represents nearly 2.37% of its market capitalization.

Anthera Pharmaceuticals, Inc. 13F Filings

At the end of 06/30/2017 reporting period, 17 institutional holders increased their position in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by some 749,461 shares, 47 decreased positions by 1,347,224 and 4 held positions by 874,926. That puts total institutional holdings at 2,971,611 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 160,887 shares while 27 institutional investors sold out their entire positions totaling 769,276 shares.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Insider Trades

Multiple company employees have indulged in significant insider trading. Anthera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Thompson John Craig has acquired 8,550 shares of Anthera Pharmaceuticals, Inc. (ANTH) in trading session dated Sep. 20, 2017. These shares are worth $11,286 and were traded at $1.32 each. The SEC filing shows that Thompson John Craig performed a purchase of 10,400 shares. The President & CEO added these shares by way of transaction on Sep. 07, 2017. The company’s shares were assimilated at $1.43 per share worth to an investment of some $14,872 on account of Thompson John Craig.

Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. (ANTH) in the open market. In a transaction dated Sep. 07, 2017, the shares were bought at an average price of $1.34, giving away a sum of $6,700. After this purchase, 16,793 common shares of ANTH are directly owned by the insider, with total stake valued at $31,907.

In the transaction dated Nov. 13, 2015, the great number of shares disposed came courtesy the Chief Medical Officer; Hislop Colin disposed a total of 1,563 shares at an average price of $42.48, amounting to approximately $66,396. The insider now directly owns 2,631 shares worth $4,999.

Anthera Pharmaceuticals, Inc. (ANTH) Analyst Guide

Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.

Previous articleAnalyzing Stocks On Analyst Opinion: Vital Therapies, Inc. (VTL), RADA Electronic Industries Ltd. (RADA)
Next articlePhotoMedex, Inc. (PHMD) loses confidence of 2 hedge fund managers